OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants David Bailey - President, CEO & Director Fred Hite - CFO, Principal Financial & Accounting Officer, COO and Director Conference Call Participants Philip Taylor - Gilmartin Group LLC David Turkaly - Citizens JMP Securities, LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to the OrthoPediatrics Corporation Third Quarter 2025 Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.18 per share a year ago.
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2025 Sales Call October 9, 2025 4:30 PM EDT Company Participants David Bailey - President, CEO & Director Fred Hite - CFO, Principal Financial & Accounting Officer, COO and Director Conference Call Participants Hannah Jeffrey - The Gilmartin Group Ryan Zimmerman - BTIG, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Ravi Misra - Truist Securities, Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division David Turkaly - Citizens JMP Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the OrthoPediatrics Corporation's Third Quarter 2025 Preliminary Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David R. Bailey - President, CEO & Director Fred L.
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.23 per share a year ago.
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group, IR David Bailey - President and CEO Fred Hite - Chief Operating and Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the OrthoPediatrics Corporation First Quarter 2025 Earnings Conference call.
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group, IR David Bailey - President and CEO Fred Hite - Chief Operating and Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Rick Wise - Stifel Matthew O'Brien - Piper Sandler Joseph Conway - Needham & Company Operator Hello. And welcome to OrthoPediatrics Corporation's Fourth Quarter and Full Year 2024 Earnings Conference Call.
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.